1-4 of 4
Paul Strumph
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program

Free
Thomas Danne, Bertrand Cariou, John B. Buse, Satish K. Garg, Julio Rosenstock, Phillip Banks, Jake A. Kushner, Darren K. McGuire, Anne L. Peters, Sangeeta Sawhney, Paul Strumph
Journal: Diabetes Care
Diabetes Care 2019;42(5):919–930
https://doi.org/10.2337/dc18-2149
Published: 04 March 2019
View articletitled, Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Open the PDF for Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program in another window
Includes: Supplementary data
Journal Articles

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

Free
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A. Kushner, Pablo Lapuerta, Darren K. McGuire, Anne L. Peters, Sangeeta Sawhney, Paul Strumph
Journal: Diabetes Care
Diabetes Care 2018;41(9):1981–1990
https://doi.org/10.2337/dc18-0342
Published: 24 June 2018
View articletitled, HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Open the PDF for HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study in another window
Includes: Supplementary data
Journal Articles

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

Free
John B. Buse, Satish K. Garg, Julio Rosenstock, Timothy S. Bailey, Phillip Banks, Bruce W. Bode, Thomas Danne, Jake A. Kushner, Wendy S. Lane, Pablo Lapuerta, Darren K. McGuire, Anne L. Peters, John Reed, Sangeeta Sawhney, Paul Strumph
Journal: Diabetes Care
Diabetes Care 2018;41(9):1970–1980
https://doi.org/10.2337/dc18-0343
Published: 24 June 2018
View articletitled, Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
Open the PDF for Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study in another window
Includes: Supplementary data
Journal Articles

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Open Access
Arthur T. Sands, Brian P. Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W. Bode, Satish K. Garg, John B. Buse, Phillip Banks, Rubina Heptulla, Marc Rendell, William T. Cefalu, Paul Strumph
Journal: Diabetes Care
Diabetes Care 2015;38(7):1181–1188
https://doi.org/10.2337/dc14-2806
Published: 11 June 2015
View articletitled, Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Open the PDF for Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes in another window
Includes: Supplementary data